Radiopharmaceuticals for single-photon emission computed tomography brain imaging

In the past 10 years, significant progress on the development of new brain-imaging agents for single-photon emission computed tomography has been made. Most of the new radiopharmaceuticals are designed to bind specific neurotransmitter receptor or transporter sites in the central nervous system. Most of the site-specific brain radlopharmaceuticals are labeled with I-123. Results from imaging of benzodiazepine (gamma-aminobutyric acid) receptors by [I-123]iomazenil are useful in identifying epileptic seizure foci and changes of this receptor in psychiatric disorders. Imaging of dopamine D2/D3 receptors ([I-123]iodobenzamide and [I-123]epidepride) and transporters [I-123]CIT (2-beta-carboxymethoxy-3-beta(4-iodophenyl)tropane) and [I-123]FP-beta-CIT (N-propyl-2-beta-carboxymethoxy-3-beta(4-iodophenyl)-nortropane has proven to be a simple but powerful tool for differential diagnosis of Parkinson's and other neuro-degenerative diseases. A Tc-99m-labeled agent, [Tc-99m]TRODAT (technetium, 2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo [3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] ethanethiolato(3-)]oxo-[1R-(exo-exo)]-), for imaging dopamine transporters in the brain has been successfully applied in the diagnosis of Parkinson's disease. Despite the fact that I-123 radiopharmaceuticals have been widely used in Japan and in Europe, clinical application of I-123-labeled brain radiopharmaceuticals in the United States is limited because of the difficulties in supplying such agents. Development of Tc-99m agents will likely extend the application of site-specific brain radiopharmaceuticals for routine applications in aiding the diagnosis and monitoring treatments of various neurologic and psychiatric disorders. Copyright 2003, Elsevier Science (USA). All rights reserved.